0.09 % to Target, Jefferies Reiterates ‘”Hold”’ Rating on West Pharm (NYSE:WST) Shares Today

September 17, 2017 - By Vivian Park

 0.09 % to Target, Jefferies Reiterates ‘

Investors sentiment decreased to 0.96 in Q4 2016. Its down 0.05, from 1.01 in 2016Q3. It dropped, as 31 investors sold West Pharmaceutical Services Inc. shares while 97 reduced holdings. 45 funds opened positions while 78 raised stakes. 66.40 million shares or 1.35% more from 65.52 million shares in 2016Q3 were reported.

Blackrock Fund Advsr owns 0.04% invested in West Pharmaceutical Services Inc. (NYSE:WST) for 2.82 million shares. Raymond James Associates accumulated 63,225 shares. Federated Investors Pa holds 0.01% or 33,745 shares in its portfolio. Sterling Cap Mngmt Lc accumulated 397,954 shares. Trexquant L P reported 2,907 shares stake. Cwm Lc has 0% invested in West Pharmaceutical Services Inc. (NYSE:WST) for 45 shares. Parametrica Limited invested 0.57% in West Pharmaceutical Services Inc. (NYSE:WST). Rhumbline Advisers accumulated 156,315 shares. National Inv Wi accumulated 2,394 shares or 0.22% of the stock. Apriem Advsr reported 0% stake. Comml Bank Of America Corp De reported 747,341 shares stake. Magee Thomson Inv Limited Liability Company accumulated 140,000 shares. 11,042 are held by Guggenheim Capital Limited Liability Com. Liberty Mutual Gp Asset has 0.1% invested in West Pharmaceutical Services Inc. (NYSE:WST). Azimuth Management Limited Liability Company stated it has 0.36% in West Pharmaceutical Services Inc. (NYSE:WST).

Since May 2, 2017, it had 0 insider purchases, and 2 sales for $5.63 million activity. 4,124 West Pharmaceutical Services Inc. (NYSE:WST) shares with value of $384,816 were sold by Malone Daniel. Another trade for 54,996 shares valued at $5.25 million was made by FEDERICI WILLIAM J on Thursday, May 18.

West Pharm (NYSE:WST) Rating Reaffirmed

In an analyst note revealed to investors and clients on 11 September, The “Hold” rating of West Pharm (NYSE:WST) shares was reconfirmed at Jefferies, who now has a $96.0 price target on the stock. Jefferies’s price target gives a possible upside of 0.09 % from the last stock price of the company.

Investors sentiment decreased to 0.96 in Q4 2016. Its down 0.05, from 1.01 in 2016Q3. It dropped, as 31 investors sold West Pharmaceutical Services Inc. shares while 97 reduced holdings. 45 funds opened positions while 78 raised stakes. 66.40 million shares or 1.35% more from 65.52 million shares in 2016Q3 were reported.

Blackrock Fund Advsr owns 0.04% invested in West Pharmaceutical Services Inc. (NYSE:WST) for 2.82 million shares. Raymond James Associates accumulated 63,225 shares. Federated Investors Pa holds 0.01% or 33,745 shares in its portfolio. Sterling Cap Mngmt Lc accumulated 397,954 shares. Trexquant L P reported 2,907 shares stake. Cwm Lc has 0% invested in West Pharmaceutical Services Inc. (NYSE:WST) for 45 shares. Parametrica Limited invested 0.57% in West Pharmaceutical Services Inc. (NYSE:WST). Rhumbline Advisers accumulated 156,315 shares. National Inv Wi accumulated 2,394 shares or 0.22% of the stock. Apriem Advsr reported 0% stake. Comml Bank Of America Corp De reported 747,341 shares stake. Magee Thomson Inv Limited Liability Company accumulated 140,000 shares. 11,042 are held by Guggenheim Capital Limited Liability Com. Liberty Mutual Gp Asset has 0.1% invested in West Pharmaceutical Services Inc. (NYSE:WST). Azimuth Management Limited Liability Company stated it has 0.36% in West Pharmaceutical Services Inc. (NYSE:WST).

Since May 2, 2017, it had 0 insider purchases, and 2 sales for $5.63 million activity. 4,124 West Pharmaceutical Services Inc. (NYSE:WST) shares with value of $384,816 were sold by Malone Daniel. Another trade for 54,996 shares valued at $5.25 million was made by FEDERICI WILLIAM J on Thursday, May 18.

West Pharmaceutical Services Inc. (NYSE:WST) Ratings Coverage

Among 3 analysts covering West Pharmaceutical Services (NYSE:WST), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. West Pharmaceutical Services has $115 highest and $69 lowest target. $92’s average target is -4.08% below currents $95.91 stock price. West Pharmaceutical Services had 10 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has “Market Perform” rating given on Wednesday, September 21 by Wells Fargo. Jefferies maintained West Pharmaceutical Services Inc. (NYSE:WST) rating on Tuesday, June 6. Jefferies has “Hold” rating and $9000 target. The stock of West Pharmaceutical Services Inc. (NYSE:WST) earned “Buy” rating by Janney Capital on Friday, January 8. Jefferies upgraded the stock to “Buy” rating in Friday, September 15 report. The firm has “Hold” rating given on Thursday, July 27 by Jefferies. The stock of West Pharmaceutical Services Inc. (NYSE:WST) has “Hold” rating given on Thursday, June 29 by Jefferies. The stock of West Pharmaceutical Services Inc. (NYSE:WST) has “Hold” rating given on Monday, September 11 by Jefferies. The rating was upgraded by Wells Fargo on Friday, October 28 to “Outperform”. As per Tuesday, March 22, the company rating was initiated by Wells Fargo. The stock of West Pharmaceutical Services Inc. (NYSE:WST) has “Hold” rating given on Tuesday, August 4 by Zacks.

The stock increased 4.61% or $4.23 on September 15, reaching $95.91. About 761,446 shares traded or 112.33% up from the average. West Pharmaceutical Services Inc. (NYSE:WST) has risen 33.75% since September 17, 2016 and is uptrending. It has outperformed by 17.05% the S&P500.

Wall Street await West Pharmaceutical Services Inc. (NYSE:WST) to release earnings on October, 26. Analysts forecast earnings per share of $0.53, exactly $0.00 or 0.00 % from 2014’s $0.53 EPS. The expected WST’s profit could reach $39.23 million giving the stock 45.24 P/E in the case that $0.53 earnings per share is reported. After posting $0.51 EPS for the previous quarter, West Pharmaceutical Services Inc.’s analysts now forecast 3.92 % EPS growth.

West Pharmaceutical Services, Inc. is a maker of packaging components and delivery systems for injectable drugs and healthcare products. The company has market cap of $7.10 billion. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services. It has a 40.96 P/E ratio. The Company’s divisions include Proprietary Products and Contract-Manufactured Products.

More news for West Pharmaceutical Services Inc. (NYSE:WST) were recently published by: Nasdaq.com, which released: “West Pharmaceutical Services (WST) Shares Cross Above 200 DMA” on September 01, 2017. Prnewswire.com‘s article titled: “West Announces Fall Investor Conference Schedule” and published on August 25, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: